Lantheus (NASDAQ:LNTH) Shares Down 5.7% – What’s Next?

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) dropped 5.7% on Monday . The stock traded as low as $103.92 and last traded at $103.5780. 478,643 shares were traded during mid-day trading, a decline of 50% from the average session volume of 960,882 shares. The stock had previously closed at $109.89.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $110.00 price target on shares of Lantheus in a research note on Tuesday, March 17th. Truist Financial reaffirmed a “buy” rating and set a $115.00 price objective (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. Finally, Mizuho upped their price target on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Stock Performance

The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The company has a 50 day moving average of $98.54 and a two-hundred day moving average of $81.62. The company has a market capitalization of $6.76 billion, a PE ratio of 25.10 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter in the previous year, the firm posted $1.53 earnings per share. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts predict that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Versant Capital Management Inc grew its stake in shares of Lantheus by 33.0% during the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after purchasing an additional 146 shares during the period. Abel Hall LLC boosted its holdings in Lantheus by 4.6% in the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after buying an additional 172 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 197 shares in the last quarter. Blue Trust Inc. raised its position in shares of Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after buying an additional 230 shares during the last quarter. Finally, Vident Advisory LLC lifted its stake in shares of Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after buying an additional 230 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.